JP2022538222A5 - - Google Patents

Info

Publication number
JP2022538222A5
JP2022538222A5 JP2021576274A JP2021576274A JP2022538222A5 JP 2022538222 A5 JP2022538222 A5 JP 2022538222A5 JP 2021576274 A JP2021576274 A JP 2021576274A JP 2021576274 A JP2021576274 A JP 2021576274A JP 2022538222 A5 JP2022538222 A5 JP 2022538222A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
acid sequence
polypeptide according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538222A (ja
JP7847433B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/039682 external-priority patent/WO2020264208A1/en
Publication of JP2022538222A publication Critical patent/JP2022538222A/ja
Publication of JP2022538222A5 publication Critical patent/JP2022538222A5/ja
Priority to JP2025138827A priority Critical patent/JP2026000901A/ja
Application granted granted Critical
Publication of JP7847433B2 publication Critical patent/JP7847433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576274A 2019-06-26 2020-06-25 Egfr抗原結合断片およびそれを含む組成物 Active JP7847433B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138827A JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866749P 2019-06-26 2019-06-26
US62/866,749 2019-06-26
US202063043486P 2020-06-24 2020-06-24
US63/043,486 2020-06-24
PCT/US2020/039682 WO2020264208A1 (en) 2019-06-26 2020-06-25 Egfr antigen binding fragments and compositions comprising same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138827A Division JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2022538222A JP2022538222A (ja) 2022-09-01
JP2022538222A5 true JP2022538222A5 (cg-RX-API-DMAC7.html) 2023-07-04
JP7847433B2 JP7847433B2 (ja) 2026-04-17

Family

ID=74060335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576274A Active JP7847433B2 (ja) 2019-06-26 2020-06-25 Egfr抗原結合断片およびそれを含む組成物
JP2025138827A Pending JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138827A Pending JP2026000901A (ja) 2019-06-26 2025-08-22 Egfr抗原結合断片およびそれを含む組成物

Country Status (12)

Country Link
US (1) US20230312729A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990499A4 (cg-RX-API-DMAC7.html)
JP (2) JP7847433B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038356A (cg-RX-API-DMAC7.html)
CN (1) CN114729056A (cg-RX-API-DMAC7.html)
AU (1) AU2020303586A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143522A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003435A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000404A2 (cg-RX-API-DMAC7.html)
IL (1) IL289100A (cg-RX-API-DMAC7.html)
MX (1) MX2021015882A (cg-RX-API-DMAC7.html)
WO (1) WO2020264208A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976098A4 (en) 2019-05-31 2023-01-18 Zymeworks Inc. METHOD OF USING A BISPECIFIC ANTIGEN-BINDING CONSTRUCT THAT TARGETS HER2 FOR THE TREATMENT OF BILAGE DUCT CANCER
PH12022553407A1 (en) 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
CN117616137A (zh) * 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
US20240400696A1 (en) 2023-04-17 2024-12-05 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
KR20260114559A (ko) 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療c1s介導的疾病和病症的組成物、劑量和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
WO2013059524A2 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
EA201691765A1 (ru) * 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
BR112018007703A2 (pt) * 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
IL307684B2 (en) * 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same

Similar Documents

Publication Publication Date Title
JP7496091B2 (ja) 合理的に設計された新規なタンパク質組成物
CN114341186B (zh) 双特异性抗LRRC15和CD3ε抗体
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
CN115605504A (zh) 新型il-21前药及其使用方法
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
EP4047018B1 (en) Tetravalent bispecific antibody against pd-1 and vegf, preparation method therefor, and use thereof
CN113166220A (zh) 创新细胞因子前药
JP2023531494A5 (cg-RX-API-DMAC7.html)
TW201815820A (zh) 雙特異性t細胞活化抗原結合分子
CN106573986A (zh) 多特异性抗体
CN113968910A (zh) 四价对称双特异性抗体
JP2026004299A5 (cg-RX-API-DMAC7.html)
CA3143522A1 (en) Egfr antigen binding fragments and compositions comprising same
JP2025540100A (ja) 突然変異体il-2ポリペプチドおよびil-2プロドラッグ
EP4263584A1 (en) Combination therapy for the treatment of cancer
EP4559932A1 (en) Multispecific antibody and use thereof
US20220127362A1 (en) Tetravalent bispecific antibody against pd-1/lag-3, preparation method therefor, and use thereof
CN120225557A (zh) 特异于跨膜激活物和caml相互作用物(taci)的抗原结合蛋白
KR20230003114A (ko) TGFβR2 세포외 도메인 절단된 분자, TGFβR2 세포외 도메인 절단된 분자와 항-EGFR 항체의 융합 단백질, 및 융합 단백질의 항종양 용도
RU2022101309A (ru) Антигенсвязывающие фрагменты для egfr и композиции, содержащие их
WO2025068449A1 (en) Knob domain proteins
HK40097873A (en) Combination therapy for the treatment of cancer
JP2025511000A5 (cg-RX-API-DMAC7.html)
HK40061166A (en) Tetravalent bispecific antibody, preparation method therefor, and use thereof
HK40075930A (en) TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN